Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate
pamrevlumab's safety and efficacy in non-ambulatory subjects with DMD.